A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD007, A Humanized gpA33 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients With Relapsed/Refractory Metastatic Colorectal Carcinoma

Trial Profile

A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD007, A Humanized gpA33 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients With Relapsed/Refractory Metastatic Colorectal Carcinoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs MGD 007 (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions; First in man
  • Sponsors MacroGenics
  • Most Recent Events

    • 26 Oct 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Jun 2018.
    • 02 Aug 2017 According to a MacroGenics media release, the company has initiated various expansion cohorts to define a recommended dose and schedule.
    • 08 Feb 2017 Planned End Date changed from 1 Mar 2017 to 1 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top